Versantis AG

Versantis is a Swiss pharmaceutical company developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide.

Its lead candidate, VS-01, is currently at preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 received Orphan Drug Designations by both the FDA and EMA. In addition, with a diagnostic test and a therapy for chronic patients, Versantis pipeline promises to answer other needs in liver diseases representing large market opportunities.